Medical News Story (Hep C Chronic Fatigue)

Medical News Story
News-Medical.Net - In an article published in the Journal of Correctional Health Care , researchers from the National Development and Research Institutes, Inc. (NDRI) reported on an evaluation of an intervention program within a prison system addressing Hepatitis C

Vertex Pharmaceuticals
Forbes - Deutsche Bank Securities initiated coverage of Vertex Pharmaceuticals with a "buy' rating and said the development-stage drug company's promising experimental drug candidate VX-950 has "gold standard" potential as a hepatitis C treatment. "Despite a

Human Genome tumbles on mixed drug data
Investors Business Daily - BOSTON (MarketWatch) -- Human Genome Sciences shares tumbled Tuesday following the release of mixed Phase II clinical data for its biologic drug candidate to treat hepatitis C, Albuferon. Shares of Human Genome sank 20% to close at $10.89. In a

Human Genome tumbles on mixed drug data
Investors Business Daily - BOSTON (MarketWatch) -- Human Genome Sciences shares tumbled Tuesday following the release of mixed Phase II clinical data for its biologic drug candidate to treat hepatitis C, Albuferon. Shares of Human Genome sank 15% to $11.67 in late morning

VGX Pharmaceuticals and DowpharmaSM Sign Research and Development
WebWire - Blue Bell, PA - February 28, 2006, VGX Pharmaceuticals and DowpharmaSM contract manufacturing services, a business unit of The Dow Chemical Company (NYSE: DOW), today announced they have signed a Research and Development Agreement to advance the